CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank58
5Y CAGR+30.9%
Studio
Year-over-Year Change

Enterprise value to sales ratio

5Y CAGR
+30.9%/yr
Long-term compound
Percentile
P58
Within normal range
vs 5Y Ago
3.8x
Strong expansion
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
20257.60+1700.3%
20240.42-61.6%
20231.10+183.0%
2022-1.32-152.6%
20212.52+27.3%
20201.98-47.4%
20193.76-41.4%
20186.41-24.3%
20178.48-56.6%
201619.52-